Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01185639 · ClinicalTrials.gov registry record · NA
Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer
A NA study of Liver Cancer and Non-Small-Cell Lung Carcinoma, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 29
- Enrollment target
- 2
- Study locations
NCT01185639: Completed NA study of Liver Cancer and Non-Small-Cell Lung Carcinoma, sponsored by Wake Forest University Health Sciences.
NCT01185639 is a NA study of Liver Cancer and Non-Small-Cell Lung Carcinoma that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 29 participants, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01185639, a NA study of Liver Cancer and Non-Small-Cell Lung Carcinoma, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 29 participants
- Enrollment target
- 2
- Study locations
Study Summary
This protocol is a single arm phase II multi-center trial evaluating the efficacy of Stereotactic Body Radiation Therapy (SBRT) in patients with oligometastatic non-small cell lung cancer (NSCLC) with response or stable disease after 4 cycles of first-line chemotherapy. The core hypothesis tested is that SBRT after 4 cycles of first-line chemotherapy is feasible, safe, provides durable local control of treated lesions and improves time to progression compared to historical controls. Patients are eligible for enrollment if they have metastatic NSCLC with ≤5 lesions amenable to SBRT.
Primary Outcome
Actuarial progression-free survival will be determined using the product-limit method of Kaplan and Meier and will be reported with an exact 95% confidence interval. Using the RECIST criteria including progression of the protocol treated tumors, non-protocol treated tumors and the development of new metastatic disease. Only protocol treated tumors will be determined by RECIST defined as complete lesion disappearance or \<25%or original size; partial \>30% decrease of target lesion; stable \<30%
Conditions Studied
Interventions
- RADIATION stereotactic body radiation therapy
Study Locations (2)
North Carolina
- Coastal Carolina Radiation Oncology - Wilmington
- Wake Forest University Health Sciences - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2010-08 |
| Est. Completion | 2016-06-27 |
| Phase | NA |
What the finished NCT01185639 record still lists
NCT01185639 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (94% lower).
The record links to 3 conditions, with Liver Cancer appearing as the primary indexed condition, and to 1 intervention - of which stereotactic body radiation therapy is the first listed.
NCT01185639 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT01185639 about?
NCT01185639 is a clinical study titled "Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer". This protocol is a single arm phase II multi-center trial evaluating the efficacy of Stereotactic Body Radiation Therapy (SBRT) in patients with oligometastatic non-small cell lung cancer (NSCLC) with response or stable disease after 4 cycles of first-line chemotherapy. The core hypothesis tested is...
What is the current status of trial NCT01185639?
This trial is currently completed. It is a NA study. The enrollment target is 29 participants. The study started on 2010-08. Estimated completion is 2016-06-27.
What conditions does trial NCT01185639 study?
This clinical trial studies the following conditions: Liver Cancer, Non-Small-Cell Lung Carcinoma, Adrenal Cancer.
What interventions are being tested in trial NCT01185639?
The interventions under investigation include: stereotactic body radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT01185639?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01185639 being conducted?
This trial has 2 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01185639's enrollment target sits among peer trials
29 49th of 78 higher than 30 of 78 other Liver Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Liver Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Feasibility Study of CBCT for IGRT in Cancer Patients
RECRUITING · NA
-
vGRID SBRT: A Phase I Clinical Trial in Unresectable or Metastatic HCC
RECRUITING · NA
-
Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis
RECRUITING · NA
-
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
RECRUITING · NA
-
HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
RECRUITING · NA
-
Interventional Radiology Liver Directed Therapies and Hypofractionated Image-Guided Radiation Therapy in Veteran and Non-Veteran, Non-surgical Hepatocellular Carcinoma Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia